SG10201506761XA - Deuterated analogs of pridopidine useful as dopaminergic stabilizers - Google Patents
Deuterated analogs of pridopidine useful as dopaminergic stabilizersInfo
- Publication number
- SG10201506761XA SG10201506761XA SG10201506761XA SG10201506761XA SG10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA
- Authority
- SG
- Singapore
- Prior art keywords
- pridopidine
- useful
- deuterated analogs
- dopaminergic stabilizers
- dopaminergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070385 | 2010-09-03 | ||
| US38085110P | 2010-09-08 | 2010-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201506761XA true SG10201506761XA (en) | 2015-10-29 |
Family
ID=44653278
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013014022A SG188298A1 (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| SG10201506761XA SG10201506761XA (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013014022A SG188298A1 (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20130197031A1 (en) |
| EP (1) | EP2611759A1 (en) |
| JP (1) | JP2013536825A (en) |
| KR (1) | KR20140008297A (en) |
| CN (1) | CN103249697B (en) |
| AU (2) | AU2011298382A1 (en) |
| BR (1) | BR112013005125A2 (en) |
| CA (1) | CA2810092A1 (en) |
| CL (1) | CL2013000604A1 (en) |
| EA (1) | EA201390332A1 (en) |
| IL (1) | IL224776A (en) |
| MX (1) | MX2013002453A (en) |
| NZ (1) | NZ608120A (en) |
| PE (1) | PE20140105A1 (en) |
| PH (1) | PH12013500406A1 (en) |
| SG (2) | SG188298A1 (en) |
| WO (1) | WO2012028635A1 (en) |
| ZA (1) | ZA201301902B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| JP5393654B2 (en) * | 2007-04-12 | 2014-01-22 | イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク | N-oxide and / or di-N-oxide derivatives of dopamine receptor stabilizers / modulators exhibiting an improved cardiovascular side effect profile |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (en) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | A kind of new Puli many determines hydrochloride polymorph form |
| UY34503A (en) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | PRIDOPIDINE BROMHYDRATE SALT |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| IN2015DN01662A (en) | 2012-09-18 | 2015-07-03 | Auspex Pharmaceuticals Inc | |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138130A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| JP6932641B2 (en) | 2015-03-06 | 2021-09-08 | オースペックス ファーマシューティカルズ インコーポレイテッド | Methods for the treatment of abnormal involuntary movement disorders |
| AR105434A1 (en) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | PROCESS TO PREPARE PRIDOPIDINE |
| CA3015512C (en) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| WO2018053287A1 (en) | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| DK4005570T3 (en) | 2016-09-16 | 2024-08-19 | Prilenia Neurotherapeutics Ltd | PRIDOPIDINE FOR USE IN THE TREATMENT OF REET'S SYNDROME |
| AU2018210145B2 (en) | 2017-01-20 | 2023-06-29 | Agency For Science, Technology And Research | Use of pridopidine for the treatment of fragile X syndrome |
| US10459055B2 (en) * | 2017-04-07 | 2019-10-29 | Case Western Reserve University | System and method for reduced field of view MR fingerprinting for parametric mapping |
| BR112020003119A2 (en) | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | method of treating amyotrophic lateral sclerosis with pridopidine |
| EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3678664A1 (en) | 2017-09-08 | 2020-07-15 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism |
| MX2022010006A (en) | 2020-02-13 | 2022-09-19 | Prilenia Neurotherapeutics Ltd | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent. |
| JP7603713B2 (en) | 2020-05-04 | 2024-12-20 | プリレニア ニューロセラピューティクス リミテッド | Treatment of viral infections, diseases, or disorders using selective S1R agonists |
| AU2021275863A1 (en) * | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| WO2021232096A1 (en) | 2020-05-20 | 2021-11-25 | Nthalmic Holding Pty Ltd | Methods and apparatus to manage meibomian gland deficiencies |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (en) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | SULFAMOYL-HETEROARILPIRAZOLE COMPOUNDS AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS |
| SE9904724D0 (en) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904723D0 (en) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| DE10123129A1 (en) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US7004629B2 (en) | 2003-07-26 | 2006-02-28 | Arthur Joseph Shrader | Method and apparatus for hanging a resealable bag |
| ES2346452T3 (en) | 2004-06-08 | 2010-10-15 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | NEW DISABLED PHENYLPIPERIDINS / PIPERAZINS USED AS MODULATORS OF THE DOPAMINE NEUROTRANSMISSION. |
| ES2659577T3 (en) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Process for the synthesis of 4- (3-methanesulfonylphenyl) -1-N-propyl-piperidine |
| CN101309917B (en) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | Deuterated inhibitor of gastric H+, K+-ATPase with enhanced therapeutic properties |
| SE529246C2 (en) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | New disubstituted phenyl-piperidines as modulators of dopamine neurotransmission |
| CN101360742A (en) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | Substituted phenylpiperidines with serotonin-derived activity and enhanced therapeutic properties |
| CA2629514A1 (en) | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JP5393654B2 (en) | 2007-04-12 | 2014-01-22 | イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク | N-oxide and / or di-N-oxide derivatives of dopamine receptor stabilizers / modulators exhibiting an improved cardiovascular side effect profile |
| US20100197712A1 (en) * | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| US8288414B2 (en) * | 2007-09-12 | 2012-10-16 | Deuteria Pharmaceuticals, Inc. | Deuterium-enriched lenalidomide |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EP2611759A1 (en) * | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (en) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | A kind of new Puli many determines hydrochloride polymorph form |
| UY34503A (en) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | PRIDOPIDINE BROMHYDRATE SALT |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| WO2014052935A2 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| BR112015006623A2 (en) | 2012-09-27 | 2017-07-04 | Teva Pharma | laquinimod and pridopidine for the treatment of neurodegenerative diseases |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX377576B (en) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | MODIFIED-RELEASE PRIDOPIDINE FORMULATIONS. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| WO2016138130A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| AR105434A1 (en) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | PROCESS TO PREPARE PRIDOPIDINE |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| US20170026730A1 (en) | 2015-07-23 | 2017-01-26 | Knowles Electronics, Llc | Microphone with temperature sensor |
| CA3015512C (en) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| WO2018053287A1 (en) | 2016-09-15 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053230A1 (en) | 2016-09-16 | 2018-03-22 | Cargill, Incorporated | Genetically modified lactate-consuming yeasts and fermentation processes using such genetically modified yeasts |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| AU2018210145B2 (en) | 2017-01-20 | 2023-06-29 | Agency For Science, Technology And Research | Use of pridopidine for the treatment of fragile X syndrome |
| BR112020003119A2 (en) | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | method of treating amyotrophic lateral sclerosis with pridopidine |
| NL2019473B1 (en) | 2017-09-01 | 2019-03-11 | Isobionics B V | Terpene Synthase producing patchoulol and elemol, and preferably also pogostol |
| EP3678664A1 (en) | 2017-09-08 | 2020-07-15 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
-
2011
- 2011-08-31 EP EP20110757801 patent/EP2611759A1/en not_active Withdrawn
- 2011-08-31 KR KR20137007971A patent/KR20140008297A/en not_active Ceased
- 2011-08-31 CN CN201180042460.5A patent/CN103249697B/en active Active
- 2011-08-31 US US13/820,024 patent/US20130197031A1/en not_active Abandoned
- 2011-08-31 MX MX2013002453A patent/MX2013002453A/en active IP Right Grant
- 2011-08-31 EA EA201390332A patent/EA201390332A1/en unknown
- 2011-08-31 CA CA 2810092 patent/CA2810092A1/en not_active Abandoned
- 2011-08-31 SG SG2013014022A patent/SG188298A1/en unknown
- 2011-08-31 JP JP2013526452A patent/JP2013536825A/en active Pending
- 2011-08-31 BR BR112013005125A patent/BR112013005125A2/en not_active IP Right Cessation
- 2011-08-31 PH PH1/2013/500406A patent/PH12013500406A1/en unknown
- 2011-08-31 WO PCT/EP2011/064954 patent/WO2012028635A1/en not_active Ceased
- 2011-08-31 PE PE2013000359A patent/PE20140105A1/en not_active Application Discontinuation
- 2011-08-31 NZ NZ60812011A patent/NZ608120A/en not_active IP Right Cessation
- 2011-08-31 AU AU2011298382A patent/AU2011298382A1/en not_active Abandoned
- 2011-08-31 SG SG10201506761XA patent/SG10201506761XA/en unknown
-
2013
- 2013-02-18 IL IL224776A patent/IL224776A/en not_active IP Right Cessation
- 2013-03-01 CL CL2013000604A patent/CL2013000604A1/en unknown
- 2013-03-13 ZA ZA2013/01902A patent/ZA201301902B/en unknown
-
2015
- 2015-12-14 US US14/968,522 patent/US20160166559A1/en not_active Abandoned
- 2015-12-14 US US14/968,510 patent/US20160095847A1/en not_active Abandoned
-
2016
- 2016-10-26 AU AU2016250390A patent/AU2016250390A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,041 patent/US20180235950A1/en not_active Abandoned
- 2018-09-17 US US16/133,192 patent/US10799492B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PE20140105A1 (en) | 2014-02-14 |
| EA201390332A1 (en) | 2013-08-30 |
| JP2013536825A (en) | 2013-09-26 |
| CA2810092A1 (en) | 2012-03-08 |
| US20130197031A1 (en) | 2013-08-01 |
| NZ608120A (en) | 2014-12-24 |
| US20190015401A1 (en) | 2019-01-17 |
| CN103249697A (en) | 2013-08-14 |
| PH12013500406A1 (en) | 2019-07-17 |
| SG188298A1 (en) | 2013-04-30 |
| IL224776A (en) | 2017-07-31 |
| CL2013000604A1 (en) | 2013-11-15 |
| US20180235950A1 (en) | 2018-08-23 |
| BR112013005125A2 (en) | 2016-08-16 |
| US10799492B2 (en) | 2020-10-13 |
| US20160095847A1 (en) | 2016-04-07 |
| CN103249697B (en) | 2016-06-15 |
| ZA201301902B (en) | 2014-05-28 |
| WO2012028635A1 (en) | 2012-03-08 |
| EP2611759A1 (en) | 2013-07-10 |
| AU2016250390A1 (en) | 2016-11-10 |
| AU2011298382A1 (en) | 2013-05-02 |
| KR20140008297A (en) | 2014-01-21 |
| MX2013002453A (en) | 2013-08-01 |
| US20160166559A1 (en) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201301902B (en) | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | |
| EP2655392A4 (en) | Cyclic nucleotide analogs | |
| AP3584A (en) | Substituted nucleotide analogs | |
| HUE047354T2 (en) | Deuterated derivatives of ivacaftor | |
| PT2709986T (en) | Deuterated derivatives of ivacaftor | |
| IL227754A0 (en) | 4-hydroxybutyric acid deuterated analogs | |
| EP2828278A4 (en) | Methods of preparing substituted nucleotide analogs | |
| IL225617A0 (en) | Cyclosporin analogs | |
| ZA201309245B (en) | Novel fluoroergoline analogs | |
| IL216632A0 (en) | Wearable utility instrument assembly | |
| EP2611451A4 (en) | Design of oligonucleotide analogs as therapeutic agents | |
| PL2658531T3 (en) | Use of glutamide stabilizers | |
| GB201311220D0 (en) | Improved structure of shoe | |
| IL225616A0 (en) | Cyclosporin analogs | |
| ZA201404034B (en) | Anhydrous antiperspirant compositions | |
| TWM388611U (en) | Improved structure of light-emitting device | |
| IL228985A0 (en) | Diazonamide analogs | |
| HK1187036A (en) | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | |
| TWM400766U (en) | Improved structure of insole | |
| TWM387196U (en) | Improved structure of LED | |
| TWM402983U (en) | Improved structure of LED | |
| TWM390954U (en) | Structure of light-emitting yarn | |
| TWM401317U (en) | Improved multi-weave structure of socks | |
| TWM400768U (en) | High heel structure | |
| TWM388315U (en) | Improved structure of hemoclip |